Outset Medical Inc

Latest Results (18.10.2025):

Outset Medical Inc reported its second-quarter 2025 financial results, showcasing continued momentum driven by robust revenue growth, increased console placements, and enhanced utilization of its Tablo Hemodialysis System. The company demonstrated significant improvements in both revenue streams and operational efficiency, positioning itself strongly for future growth.

Revenue Growth

Net revenue for the second quarter of 2025 reached $31.4 million, marking a 15% increase compared to the same period last year. This growth was primarily fueled by a 25% rise in Tablo console revenue, highlighting strong market demand for Outset Medical’s innovative dialysis solutions.

Recurring Revenue Expansion

Recurring revenue, which includes Tablo consumables and services, grew by 11% year-over-year to $22.5 million. This increase was driven by a 17% uplift in consumable revenue, reflecting higher utilization of the Tablo system across various facilities.

Improved Gross Margin

The company achieved a gross margin of 37.8% for the second quarter of 2025, or 38.4% on a non-GAAP basis. This represents a 110 basis-point improvement over the prior-year period, indicating enhanced efficiency in production and cost management.

Operational Efficiency

Operating expenses declined by nearly 30% compared to the second quarter of 2024. Additionally, Outset Medical utilized approximately 60% less cash during the first half of 2025 than in the same period last year, demonstrating significant improvements in financial management and cost control.

Strategic Partnerships and Expansion

Outset Medical signed a new enterprise agreement with one of the largest national health systems, granting Tablo access to over 100 facilities. Consequently, the Tablo system is now deployed in more than 900 acute and sub-acute sites across the United States, further expanding the company’s market presence and accessibility.